Overview

Duvelisib in Combination With CC-486 in Lymphoid Malignancy

Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug CC-486, in combination with duvelisib.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Secura Bio, Inc.
Treatments:
Azacitidine
Cc-486